Patient portal

TEMOkids

Clinical study on the safety and ease of use of a liquid formulation of the drug temozolomide developed specifically for children.

Closed, results published

Published results

Liquid formulation of temozolomide is safe and easier for children

Brief summary

Researchers have developed a liquid formulation of the drug temozolomide specifically for children. This drug is used to treat several types of cancer. The new liquid formulation is designed for children who have difficulty swallowing capsules. This study shows that the drink can be used safely and fits well into routine care.

Background

Temozolomide is a drug used to treat several types of cancer, including certain brain tumors, neuroblastoma, and other solid tumors. Until now, this drug has mainly been available as a capsule. Swallowing capsules can be difficult for young children. Researchers therefore developed a ready-to-use liquid formulation of temozolomide specifically for children.

Purpose of the study

The researchers wanted to determine whether the new liquid formulation can be used safely in children. They also studied how the drug is absorbed by the body and whether the drink is easy to use.

How was the study conducted?

The study included 43 children between one and almost fifteen years of age. They had different types of solid tumors that required treatment with temozolomide. The children received the new drink either on its own or in combination with other cancer drugs. The researchers monitored how the drug was absorbed by the body through blood samples and evaluated the safety and ease of use of the treatment.

What were the results?

The results show that the new liquid formulation of temozolomide can be used safely in children. Few serious side effects related to temozolomide were observed during the study. No unexpected serious side effects were reported.

The researchers conclude that the liquid formulation can be used effectively in routine care. The study also provides greater insight into how the drug is absorbed by children's bodies. This information helps ensure the drug is used appropriately.

The study was not designed to determine whether the drug is more effective than the existing capsules. However, it does show that the new liquid formulation may be a suitable alternative for children who have difficulty swallowing capsules.

What is the next step?

Because there is a need for a child-friendly formulation of temozolomide, a European program has been launched to make the new drink available to children who are eligible for it. Further research may help expand the use of the liquid formulation.

Learn more

This study, the TEMOkids Phase 1 study, was conducted at twelve centers across Europe. The results were presented at the 55th annual congress of the Société Internationale d’Oncologie Pédiatrique (SIOP) in October 2023.

Would you like to read the scientific publication? Please look here: Abbou S, et al. Assessment of a novel ready-to-use temozolomide oral suspension in children with solid tumors: results of TEMOkids, a population pharmacokinetic, acceptability and safety phase-1 study. Pediatr Blood Cancer. 2023;70: e30748, abstr O213.